Search Results - "Habuchi T"

This result is not displayed to guests.
Login for full access.

3-Dimensional Stress Analysis of Virial-Limit Coils.

Authors: Habuchi, T. Tsutsui, H. Tsuji-Iio, S. et al.

Source: IEEE Transactions on Applied Superconductivity. Jun2010, Vol. 20 Issue 3, p1924-1927. 4p.

Subjects: Electric coils, Electromagnetism, Finite element method, Bending stresses, Magnetism

This result is not displayed to guests.
Login for full access.

Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.

Authors: Kakinuma, H. Tsuchiya, N. Habuchi, T. et al.

Source: Prostate Cancer & Prostatic Diseases. 2004, Vol. 7 Issue 4, p333-337. 5p. 4 Charts.

Somatic mutation of PTEN in bladder carcinoma.

Authors: Aveyard, J S Skilleter, A Habuchi, T et al.

Source: British Journal of Cancer. 5/15/99, Vol. 80 Issue 5/6, p904. 5p.

Lymphovascular invasion is significantly associated with biochemical relapse after radical prostatectomy even in patients with pT2N0 negative resection margin.

Authors: Mitsuzuka, K Narita, S Koie, T et al.

Source: Prostate Cancer & Prostatic Diseases. Mar2015, Vol. 18 Issue 1, p25-30. 6p.

Impact of body mass index on clinicopathological outcome and biochemical recurrence after radical prostatectomy.

Authors: Narita, S Mitsuzuka, K Yoneyama, T et al.

Source: Prostate Cancer & Prostatic Diseases. Sep2013, Vol. 16 Issue 3, p271-276. 6p.

Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation.

Authors: Miura, M. Niioka, T. Kagaya, H. et al.

Source: Journal of Clinical Pharmacy & Therapeutics. Apr2011, Vol. 36 Issue 2, p208-216. 9p.

Inter-individual difference determinant of prednisolone pharmacokinetics for Japanese renal transplant recipients in the maintenance stage.

Authors: Miura, M. Inoue, K. Kagaya, H. et al.

Source: Xenobiotica. Dec2009, Vol. 39 Issue 12, p939-945. 7p. 3 Charts, 1 Graph.

Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients.

Authors: Miura, M. Satoh, S. Kagaya, H. et al.

Source: Journal of Clinical Pharmacy & Therapeutics. Dec2009, Vol. 34 Issue 6, p683-692. 10p. 1 Diagram, 3 Charts, 3 Graphs.

Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.

Authors: Fujiyama, N. Miura, M. Satoh, S. et al.

Source: Xenobiotica. May2009, Vol. 39 Issue 5, p407-414. 8p. 1 Diagram, 1 Chart, 3 Graphs.

No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients.

Authors: Kagaya, H. Miura, M. Satoh, S. et al.

Source: Journal of Clinical Pharmacy & Therapeutics. Apr2008, Vol. 33 Issue 2, p193-201. 9p. 4 Charts, 1 Graph.

Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.

Authors: Miura, M. Kagaya, H. Tada, H. et al.

Source: Xenobiotica. May2005, Vol. 35 Issue 5, p479-486. 8p.

Definition of a 1-Mb homozygous deletion at 9q32-q33 in a human bladder-cancer cell line.

Authors: Fujiwara, H. Emi, M. Nagai, H. et al.

Source: Journal of Human Genetics. 2001, Vol. 46 Issue 7, p372. 6p.

Association of vitamin D receptor gene polymorphism with protection against prostate cancer and benign prostate hyperplasia.

Authors: Ogawa, O Suzuki, T Habuchi, T et al.

Source: Prostate Cancer & Prostatic Diseases. 1999 Supplement 3, Vol. 2 Issue 4, pS24. 1p.

A0482 - Clinical significance of α2,3-sialylated prostate-specific antigen density and MRI for high-grade prostate cancer in biopsy-naïve men with elevated PSA level.

Authors: Yoneyama, T. Yamamoto, H. Sutoh Yoneyama, M. et al.

Source: European Urology. 2022 Supplement 1, Vol. 81, pS731-S733. 3p.

A0833 - Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old.

Authors: Numakura, K. Kobayashi, M. Hatakeyama, S. et al.

Source: European Urology. 2024 Supplement 1, Vol. 85, pS1850-S1851. 2p.

A0747 - Germline HLA-DQB1*03:01 is an independent prognostic factor for clinical outcomes in patients with urothelial cancer treated with pembrolizumab.

Authors: Narita, N. Takahashi, S. Fujiyama, N.F. et al.

Source: European Urology. 2024 Supplement 1, Vol. 85, pS1722-S1723. 2p.

A0214 - BRAF V600E mutation promoted excess of cortisol secretion in adrenal cortical adenoma.

Authors: Numakura, K. Muto, Y. Sugiyama, Y. et al.

Source: European Urology. 2024 Supplement 1, Vol. 85, pS973-S974. 2p.

P288 - Risk factors of subsequent upper urinary tract carcinoma treated with intravesical Bacillus Calmette-Guerin therapy for non-muscle-invasive bladder cancer: From multiple Japanese hospitals.

Authors: Numakura, K. Miyake, M. Kobayashi, M. et al.

Source: European Urology. 2024 Supplement 1, Vol. 85, pS398-S399. 2p.